Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ DAK Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5115091
Description
Antibody detects endogenous levels of total DAK.
This gene is a member of the family of dihydroxyacetone kinases, which have a protein structure distinct from other kinases. The product of this gene phosphorylates dihydroxyacetone, and also catalyzes the formation of riboflavin 4',5'-phosphate (aka cyclin FMN) from FAD. Several alternatively spliced transcript variants have been identified, but the full-length nature of only one has been determined.
Specifications
DAK | |
Polyclonal | |
Unconjugated | |
TKFC | |
ATP-dependent dihydroxyacetone kinase; BC021917; bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing); Dak; DHA kinase; Dha kinase/FMN cyclase; dihydroxyacetone kinase 2 homolog; dihydroxyacetone kinase 2 homolog (S. cerevisiae); DKFZP586B1621; DKFZP586B1621 protein; FAD-AMP lyase (cyclic FMN forming); FAD-AMP lyase (cyclizing); FAD-AMP lyase cyclic FMN forming; FAD-AMP lyase cyclizing; FMN cyclase; Glycerone kinase; MGC5621; NET45; RGD1311026; testis tissue sperm-binding protein Li 84P; TKFC; Triokinase; triokinase and FMN cyclase; triokinase, FMN cyclase; triokinase/FMN cyclase; Triose kinase; zgc:153296 | |
Rabbit | |
Affinity chromatography | |
RUO | |
225913, 26007, 361730 | |
-20°C | |
Liquid |
Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide | |
Q3LXA3, Q4KLZ6, Q8VC30 | |
TKFC | |
A synthesized peptide derived from human TKFC(Accession Q3LXA3), corresponding to amino acid residues G119-E169. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction